Int J Pharm

S.No Title & Authors Name Page
Preventing Inappropriate Hydroxyurea Dosing in Children by Introducing a Child-Appropriate Preparation
Gideon Koren*, Michael Lishner, Ami Ballin
 Abstract                  View                 Download                 XML

Hydroxyurea (HU) is the only FDA- approved disease- modifying drug for sickle cell disease, by inducing the production of fetal hemoglobin and thus decreasing the sickling of red blood cells. Till recently HU was available only in adult doses of 1000 mg. This meant that to aim at the standard dose of 20 mg/kg/d, most young children had to be overdosed, or the doses had to be fluctuated daily to achieve the aimed mean dose. Because adherence improves with unchanged daily dose, and due to the more than 10 fold variability in HU pharmacokinetics in children, there was an urgent need for a pediatric formulation of HU.
This issue has been solved with FDA approval of the French-originated orphan HU, Siklos, a preparation of 50 and 100 mg, which prevents the risk of inappropriate dosing in children.

Medicine Containing Herbs and Vitamins Have Eliminated 100% of Hepatitis B Virus, Prevent the Progression of Cirrhosis and Liver Cancer
Nguyen Thi Trieu*
 Abstract                  View                 Download                 XML

Immunodeficiency and viral hepatitis rate are increasing. Currently, there are a lot of treatment plans for hepatitis B in the world. However, make preparations still have limited in effectiveness, lead to high rate of cirrhosis and liver cancer worldwide, the currently available medicines cannot fully deliver their effectiveness is because they do not create a favorable environment with the presence of intermediates needed for the body to produce antibodies against the virus, not support of the NRTIs (nucleoside reverse transcriptase inhibitors); To overcome these weaknesses, the invention of the herbs and vitamins mixture have made a new breakthrough, created a “perfect cell type” with the ability of preventing the invasion of virus and destroy the “mini-chromosome” of hepatitis B virus, it has helped to improve the treatment’s effectiveness. The medicine contains the following components: Adenosma Glutinosum; Eclipta Prostrata; Phyllanthus Urinaria; Ascorbic acid; Cyanocobalamin.
Post-treatment criteria:
Virus level (HBV-DNA test): see in the blood contains complete virus (including the core and shell).
Monitoring the outcome of treatment to test for HBsAg Cobas level in HBsAg Cobas (+) patient and achieved a score of < 1 (unit: COI, standard index <1). There is a small percentage of the patient showed HBsAg Cobas (-) after 24 months. Stop the treatment after achieving these criteria. The medicine has increased the therapeutic efficacy in patients with cirrhosis and liver cancer, applicable in patients with primary liver cancer and currently used alongside with Radiofrequency Ablation or Transarterial Oily Chemo Embolization.

Ethnobotanical, Phytochemical and Pharmacological Aspects of Genus Alysicarpus
Maryam Bashir*, Muhammad Uzair, Bashir Ahm
 Abstract                  View                 Download                 XML

Plant species and their active constituents play an important role in the prevention of a variety of ailments. The genus Alysicarpus comprises of about 30 species, out of which, eight species are found in Pakistan. Only a few species of the genus Alysicarpus have been investigated for phytochemical and biological activities. A variety of potentially bioactive molecules such as alkaloids, flavonoids, phenolics, terpenoids and steroids have been isolated from various species of genus Alysicarpus. It has been reported that these species possess analgesic, anti-inflammatory, antimicrobial, antiplasmodial, larvicidal, mosquitocidal, antioxidant, hepatoprotective, antiproliferative and antifertility activity. This article aims to highlight the ethnomedicinal uses, phytochemical and pharmacological aspects of Alysicarpus species and illustrates the potential of the genus as a source of therapeutic agents.